Glycobiology institute
Executive Summary
Searle providing approximately $5 mil. to help fund a collaborative research center at Oxford University. Oxford is putting up about $1.4 mil. The center, which will house 60 Searle and Oxford scientists, will focus on the development of therapeutic agents using oligosaccharide technology. "This pioneering research in glycobiology could lead to compounds important" in the treatment of AIDS, osteo and rheumatoid arthritis, Searle Chairman Gilgore remarked.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.